Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights a significant revenue increase and a strong cash position extending into 2027, which is positive. However, the delay in COVID-19 trial data, regulatory uncertainties, and heavy reliance on partnerships introduce risk. The Dynavax partnership is a potential positive catalyst, but the lack of clear guidance and delayed data releases temper expectations. Thus, the overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
Key Financial Performance
Revenue for the full year 2025 $237.3 million compared to $28.7 million for the full year 2024, representing a significant increase. The increase was primarily due to contracts related to the BARDA contract awarded in June 2024 and revenue recognized from the Dynavax license and collaboration agreement signed in November 2025.
Cash, cash equivalents, and investments at the end of Q4 2025 $63.8 million. This reflects the company's financial position and its expectation to have a cash runway into the second quarter of 2027, supported by strategic partnerships, non-dilutive funding options, and prudent expense management.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Oral COVID-19 Vaccine Partnership: Established a partnership with Dynavax, receiving $25 million upfront and $5 million equity investment. Potential for up to $700 million in license, regulatory, and milestone fees, tiered royalties, and equity investment.
Oral Norovirus Vaccine Data: Published complete data set from clinical study in lactating mothers, showing safety, tolerability, and immunogenicity. Demonstrated potential for passive transfer of mucosal immunity to infants.
Market Expansion through Partnership: Partnership with Dynavax (now part of Sanofi) validates oral vaccine platform and extends cash runway. Potential for significant revenue through regulatory and sales milestones.
Cost Management: Entered a lease termination agreement to reduce operating expenses, saving costs by ending a lease early.
Revenue Growth: Revenue increased to $237.3 million in 2025 from $28.7 million in 2024, driven by BARDA contract and Dynavax agreement.
Focus on Key Programs: Prioritizing COVID-19 and norovirus vaccine programs, with plans to secure partnerships or funding for further development.
Platform Technology Development: Advancing oral pill vaccine platform for broader applications, including flu and HPV vaccines.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Regulatory and Clinical Trial Risks: The company faces uncertainty inherent in the clinical development and regulatory process, including the need to consult with and receive approval from BARDA regarding the timing and content of press releases related to the COVID-19 trial. Additionally, the Phase IIb trial for the oral COVID-19 vaccine candidate is still ongoing, with results from the larger KP.2 cohort not expected until late 2026, which could delay further development and commercialization.
Financial Risks: Vaxart's cash runway is projected to last until the second quarter of 2027, necessitating aggressive pursuit of strategic partnerships, non-dilutive funding, and cost management. The company is reliant on milestone payments and partnerships, such as the Dynavax agreement, to sustain operations and advance its pipeline.
Operational Risks: The company is dependent on securing partnerships or funding to advance its norovirus program and other pipeline assets. Delays or failures in securing these resources could hinder the development of its vaccine candidates.
Market and Competitive Risks: The company operates in a highly competitive vaccine market, and its oral vaccine platform must demonstrate significant advantages over existing solutions to gain market acceptance. The success of its COVID-19 and norovirus programs is critical to its competitive positioning.
Supply Chain and Manufacturing Risks: The company has not explicitly mentioned supply chain issues, but the reliance on partnerships and external funding suggests potential vulnerabilities in scaling up production and distribution if its vaccine candidates are approved.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
COVID-19 Oral Vaccine Candidate: The company is conducting a Phase IIb trial comparing its oral COVID-19 vaccine candidate to an mRNA vaccine. The trial will measure efficacy for symptomatic and asymptomatic disease, immune induction, and adverse events. Top-line data from the 400-participant sentinel cohort is expected early in Q2 2026, while data from the 5,000-subject KP.2 cohort is expected in late Q4 2026. The results will inform the potential of the COVID-19 candidate and the oral pill vaccine platform.
Norovirus Oral Vaccine Candidate: The company plans to initiate the next clinical trial of its second-generation norovirus vaccine constructs in 2026, pending a partnership or funding. Preclinical studies are exploring cross-reactivity with additional norovirus strains, with results expected later in 2026. Positive results could enhance the vaccine's value and utility.
Financial Guidance: The company expects its cash runway to extend into Q2 2027. It is actively seeking strategic partnerships, non-dilutive funding options, and managing expenses to extend this runway further.
Business Development: The company is focusing on securing partnerships or funding for its norovirus program and exploring licensing opportunities for earlier-stage assets, including seasonal and pandemic flu candidates and the HPV program.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Why is there a delay in the 400-person sentinel cohort data, and how should expectations be framed for the full Phase IIb data?
A:The delay in the 400-person sentinel cohort data is due to coordination with BARDA, which has a say in the timing and release of data. The data will now be reported in early Q2 instead of late Q1. The 400-person cohort is primarily for safety data, while the 5,000-person KP.2 cohort will provide more robust efficacy insights, expected in Q4 2026.
Q:What are the decision points for the COVID program after the sentinel data in Q2 and the larger data set in Q4?
A:The decision points involve Vaxart and BARDA overseeing the Phase IIb trial, with Dynavax deciding whether to opt-in after the Phase II package is submitted to the FDA. The sentinel 400 data will provide safety and some efficacy insights, while immunogenicity data will follow later.
Q:Will immunogenicity data be part of the Q2 update for the COVID program?
A:No, immunogenicity data will not be part of the Q2 update. It will be produced later by BARDA.
Q:Has there been any regulatory input on endpoint constructs for the norovirus second-gen candidate in the next Phase II study?
A:Yes, discussions with the FDA have occurred. The primary endpoint for the Phase IIb study is safety, along with immunogenicity data collection. Progress depends on securing a partner.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on the reasons for the delay in the 400-person sentinel cohort data, only attributing it to coordination with BARDA. Additionally, they did not provide a clear timeline for the immunogenicity data release for both the sentinel 400 and KP.2 cohorts.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AEs
Dynavax vaccine
GI response
GII strain
Jeroen
Sanofi
ability
agreement Dynavax
asset
body evidence
breast milk
candidate mother
cohort efficacy
collaboration BARDA
day
dose group
evidence potential
generation vaccine
infant norovirus
insight
lease termination
norovirus IgA
placebo
platform technology
response GI
response GII
safety
serum
stool
subject cohort
termination agreement
timing collaboration
transfer
utility
woman
VXRT Transcript
Vaxart, Inc. (VXRT) Q1 2026 Earnings Call Transcript
Unknown5-8
The company's revenue declined by 25% YoY, and net losses increased by 10% due to higher R&D expenses. Additionally, there are significant risks related to regulatory approvals, NASDAQ compliance, and financial stability. No new partnerships or positive strategic updates were announced. The lack of positive catalysts and increased uncertainties suggest a negative sentiment, likely leading to a stock price decline of -2% to -8% over the next two weeks.
Vaxart, Inc. (VXRT) Q4 2025 Earnings Call Transcript
Unknown3-12
The earnings call highlights a significant revenue increase and a strong cash position extending into 2027, which is positive. However, the delay in COVID-19 trial data, regulatory uncertainties, and heavy reliance on partnerships introduce risk. The Dynavax partnership is a potential positive catalyst, but the lack of clear guidance and delayed data releases temper expectations. Thus, the overall sentiment is neutral, with no strong catalysts for significant stock movement in the short term.
Vaxart, Inc. (VXRT) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call highlights a significant revenue increase and extended cash runway, which are positive. However, the dependency on partnerships for advancing the norovirus program and the BARDA stop work order pose risks. The Q&A session revealed uncertainty about independent trial initiation for the norovirus program, reflecting potential challenges. These mixed signals suggest a neutral sentiment, with positive financials balanced by strategic uncertainties.
Vaxart, Inc. (VXRT) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call presented a mixed outlook. Positive aspects include revenue growth, a strong cash runway, and promising vaccine developments. However, workforce reductions, dependency on external funding for trials, and uncertainties in partnerships and trial progress are concerning. The Q&A highlighted management's lack of clarity on key issues, such as the COVID-19 trial's stop work order, which raises uncertainty. Despite potential catalysts like the avian flu vaccine, uncertainties and financial challenges balance out the positives, leading to a neutral sentiment.
VXRT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
